REHOVOT, Israel, November 3 /PRNewswire/ -- Foamix Ltd, a global leader in the development of dermatological foam medications today announced that the company has extended its agreement with Galderma to develop an innovative medicated foam for an additional dermatological indication. This new treatment contains a novel drug for the therapy of certain skin diseases.
Under this agreement, Foamix will develop the foam formulation of the product and Galderma will subsequently conduct all other activities (clinical, non-clinical, etc). Foamix will receive staged payments on successful completion of the technical milestones of the project.
Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with major, medium and small pharmaceutical and cosmetic companies on a plurality of projects in the development of proprietary dermatological and gynecologic foam drugs. Additionally, the Company has an in-house pipeline of dermatological and gynecological drugs in foam presentation.
To date, Foamix has seventeen issued patents worldwide covering its foam and OilGel technology platforms and in excess of 150 pending applications of which more than a third are filed in the United States. The Company employs a leading U.S. patent counsel (WilmerHale LLC).
For additional information, please visit http://www.foamix.co.il.
Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or firstname.lastname@example.org
CONTACT: Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or